Blocked vaccine study finally sees daylight
2026-06-24
Publication, not the lab bench, is where this fight is being waged now. A study on COVID-19 vaccine effectiveness that a CDC-affiliated journal declined to run has finally appeared in an independent medical outlet, complete with peer review, revised statistical tables, and a full disclosure of its earlier rejection.
The uncomfortable question is whether science or institutional risk management set the pace. Authors report that the government-linked journal raised concerns about study design and potential misinterpretation, even though the analysis used standard case-control methods and routinely accepted endpoints such as symptomatic infection and hospitalization. The published version keeps those endpoints, adds sensitivity analyses, and clarifies how confounders like prior infection were handled through multivariable regression and propensity score adjustment.
What now looks most striking is not the effect size but the edit trail. The study finds that protection against symptomatic infection waned over time while defense against severe disease remained relatively strong, a pattern consistent with neutralizing antibody decay and more durable T-cell mediated immunity. None of that is especially radical. What is sharper is the signal that a government-adjacent journal hesitated to host data that might fuel controversy over booster policy, leaving a different publisher to absorb the argument and the scrutiny.
Loading...
